The major dark money group supporting President Donald Trump’s political and economic agenda raked in millions of dollars directly from the pharmaceutical industry’s main lobbying group — at the same time Trump backed off his position on a major drug issue and promoted a tax plan that was a windfall for the industry.

The Pharmaceutical Research and Manufacturers of America gave $2.5 million to America First Policies in 2017, according to IRS documents. America First Policies was formed by former Trump advisers in 2017 and proudly touts itself as a pro-Trump organization. The PhRMA money represented more than 10 percent of America First Policies’ revenues in 2017, according to the group’s own IRS filings.

The IRS documents were obtained by MapLight, a nonpartisan group that tracks the influence of money in politics.

While campaigning for president, Trump pledged to take action to generally reduce drug prices and to allow Medicare to negotiate lower prices for prescription medications. He then appointed a former pharmaceutical executive to run the Department of Health and Human Services, and slammed the Medicare negotiation concept after a meeting with pharmaceutical executives.

“I’ll oppose anything that makes it harder for smaller, younger companies to take the risk of bringing their product to a vibrantly competitive market,” Trump said. “That includes price-fixing by the biggest dog in the market, Medicare.”

While Trump has moved to allow limited negotiation in some parts of Medicare, he has rejected the larger policy he campaigned on, leaving it out of his prescription drug proposal released earlier this year.

Trump also passed a tax cut that benefited the pharmaceutical industry, but that has not corresponded with a drop in prescription drug prices. America First Policies launched an ad campaign to promote those tax cuts, and spent the end of the 2018 campaign promoting them. PhRMA also gave $1.5 million to the American Action Network, which aired an ad campaign in support of the tax-cut legislation.

Copyright Capital & Main